Printer Friendly

DU PONT MERCK CEO RECEIVES HONORARY DOCTORATE

 DU PONT MERCK CEO RECEIVES HONORARY DOCTORATE
 WILMINGTON, Del., May 20 /PRNewswire/ -- Joseph A. Mollica,


president and chief executive officer of The Du Pont Merck Pharmaceutical Company, received an honorary Doctor of Science degree as part of the University of Rhode Island's (URI) Centennial Commencement exercises which took place last weekend, May 16-17, on the Kingston campus.
 Mollica, one of three accomplished scientists to receive honorary doctorates at the Graduate School Commencement on Saturday, May 16, is a 1962 magna cum laude graduate of URI. He also holds M.S. and Ph.D. degrees from the University of Wisconsin.
 After completing his education, Mollica spent the first 22 years of his career in the pharmaceutical industry at the Ciba-Geigy Corporation. Rising to senior vice president for drug development, he directed a staff of 550 scientists who were developing products for North America.
 In 1987, Mollica joined Du Pont as head of its Pharmaceutical and Biotechnology Research and Development Division. There he directed a diverse staff of 1,200 physicians, chemists, engineers, statisticians, biologists and other professionals involved in all aspects of research and development.
 When Du Pont Merck was formed in January of 1991, Mollica was appointed president and chief executive officer and has lead this worldwide, Fortune 500, pharmaceutical company since its inception. He lists 21 patent/publications to his credit and serves on the boards of United States Pharmacopeia, the Pharmaceutical Manufacturers Association, the PMA Foundation, Silicon Graphics Inc. and the Philadelphia College of Pharmacy and Science.
 The Du Pont Merck Pharmaceutical Company is a Fortune 500, research- based pharmaceutical company which markets its products worldwide. Formed in 1991 as a partnership between Du Pont (NYSE: DD) and Merck & Co., Inc. (NYSE: MRK), Du Pont Merck is focused on researching, developing and delivering important pharmaceuticals to treat unmet medical needs in the fight against heart disease, cancer, arthritis, Alzheimer's disease, and virus, including AIDS. The company is also a leader in the imaging agents field; creating radiopharmaceuticals which provide high-quality diagnostic information. Worldwide revenues at Du Pont Merck for 1991 were $795 million. Company headquarters are in Wilmington.
 /delval/
 -0- 5/20/92
 /CONTACT: Suzanna Dottor of Du Pont Merck, 302-892-8500/
 (DD MRK) CO: The Du Pont Merck Pharmaceutical Company ST: Delaware IN: MTC SU:


MK -- PH006 -- 2221 05/20/92 09:48 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 20, 1992
Words:386
Previous Article:THE ECONOMIC DIMENSION OF THE CONFLICT IN BOSNIA-HERZEGOVINA
Next Article:MCI ANNOUNCES SEVEN NEW GLOBAL ADVANTAGE AGREEMENTS
Topics:


Related Articles
DU PONT MERCK NAMES ARNER ASSISTANT GENERAL COUNSEL
DU PONT MERCK NAMES HORNER MANAGING DIRECTOR FOR U.K.
DU PONT MERCK NAMES FLETCHER AS GOVERNMENT AFFAIRS MANAGER
DU PONT MERCK NAMES BLANK VP FOR WORLDWIDE MARKETING
DU PONT MERCK HONORS OUTSTANDING SALES ACHIEVEMENTS: DISTRICT OF THE YEAR AWARDS
ANTONIO J. GRILLO-LOPEZ JOINS IDEC PHARMACEUTICALS AS VICE PRESIDENT, MEDICAL AND REGULATORY AFFAIRS
ANTONIO J. GRILLO-LOPEZ JOINS IDEC PHARMACEUTICALS AS VICE PRESIDENT, MEDICAL AND REGULATORY AFFAIRS
DU PONT MERCK ANNOUNCES PERSONNEL APPOINTMENT
MEDCO RESEARCH NAMES DIRECTOR, RADIOPHARMACEUTICAL CLINICAL RESEARCH
DU PONT MERCK EXECUTIVE JOINS SYMPHONY PHARMACEUTICALS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters